Refine by
Disease Lung Articles & Analysis
172 news found
The month of May is dedicated to asthma control and education to increase awareness about the disease and how those with it can prevent or mitigate exposures to asthma triggers, allergens, and respiratory irritants. Asthma is one of the most common lifelong chronic diseases in Puerto Rico and across the rest of the United States, according to the Centers for ...
Idiopathic pulmonary fibrosis (IPF) is a devastating disease characterized by progressive scarring of the lungs, which severely impairs lung function over time. Developing effective treatments for IPF has been a challenge for the medical community, as the mechanisms driving this disease are complex and not fully understood. ...
Recent advances in the fight against severe acute inflammatory lung diseases, including COVID-19, have revealed a promising new approach to treating pulmonary hyperinflammation and long-term lung damage such as fibrosis. ...
This formulation is suitable for inhaled mRNA treatment of lung diseases. CD Bioparticles provides comprehensive solutions to the limitations researchers might encounter in drug delivery and exosome research. ...
In the realm of pulmonary research, the search to understand complex lung conditions has led to the development of various animal models. Among these, a new murine model from Tsijis et al stands out for its potential to investigate flow-induced pulmonary hypertension (PH) and compensatory lung growth (CLG). This blog outlines this innovative model, its significance, and the method of ...
TB is caused by a bacterium known as Mycobacterium tuberculosis that typically attacks the lungs, but can also attack other parts of the body. The disease can be spread from a person with the disease of the lungs or throat through the air from one person to another when they cough, sneeze, speak, or sing. ...
ScienceNews published an article last year about the spread of three types of fungi that can cause serious lung diseases. One of these was Histoplasma which causes histoplasmosis, an infection once mainly found in the Midwest, but in more recent times infections have been recorded in at least 47 states. Histoplasma capsulatum lives in the environment, ...
However, some species are known to be a serious infection risk for individuals with comorbidities such as weakened immune systems or lung disease. Of the approximately 180 species of Aspergillus, fewer than 40 of them are known to cause infections in humans according to the Centers for Disease Control and Prevention (CDC). ...
However, some species are known to be a serious infection risk for individuals with weakened immune systems or lung disease. Of the approximately 180 species of Aspergillus, fewer than 40 of them are known to cause infections in humans according to the Centers for Disease Control and Prevention (CDC). ...
Vitalograph, a global leader in the development and production of respiratory diagnostic solutions and clinical trial services, has launched the Vitalograph tremoflo® C-100 at this year’s ATS International Conference, taking place in Washington. ...
Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as diabetic kidney disease (DKD), including diabetic nephropathy (DN), type 1 and type 2 diabetes (T1D / T2D), non-alcoholic steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications like progressive ...
This collaboration could extend the reach of gene editing for liver and lung disease targets. “AskBio’s pioneering gene editing technology is a powerful complement to our modular SORT LNP genetic medicines platform, which enables the precise delivery of a wide variety of genetic cargoes to specific organs and cells, including large, complex genetic ...
ByBayer AG
” Bill Heiden, Third Pole’s Chairman added, “This strategic investment in Third Pole Therapeutics is directly aligned with both organization’s mission to advance unique, disruptive, cost-effective solutions that improve outcomes in heart and lung-failure patients. It also provides validation that Third Pole’s technology represents the best in ...
Until now, the only other options for these patients were invasive treatments such as lung volume reduction surgery or lung transplantation. The one-way Zephyr Valves are placed in a selected lobe of the lung (generally the most diseased lobe and with little to no collateral ventilation) during a bronchoscopic procedure to ...
About INV-202 INV-202 is a small molecule CB1 inverse agonist being developed by Inversago for the potential treatment of a range of cardiometabolic and fibrotic conditions, including diabetic kidney disease. It is specifically designed to preferentially block CB1 receptors in peripheral tissues such as the kidneys, gastro-intestinal tract, liver, pancreas, adipose tissues, ...
Abstract title: “Metabolomic Profiling for the Early Detection of Lung Cancer”. The results demonstrated the high accuracy of BioMark’s quantitative metabolomic platform to identify early-stage lung cancer in retrospective plasma samples from individual with smoking history compared to participants suffering from other lung ...
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference in New York on Wednesday, November 30, 2022, at 11:30 AM PT / 2:30 PM ET. ...
(NASDAQ: XAIR) a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced ...
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences in New York. ...
AMReady is a very complete consortium of institutions led by Vaxdyn and formed by the Barcelona-based international pharmaceutical manufacturer Laboratorios Reig Jofre and top groups in Immunology and infectious diseases of the National Microbiology Center (CNM) of the Spanish Institutes of Health “Carlos III” (ISCIII) in Madrid (Spain), the Faculty of Veterinary ...